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Validation of questionnaire-reported chest
wall abnormalities with a telephone
interview in Swiss childhood cancer
survivors
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Abstract
Background: Chest wall abnormalities are a poorly studied complication after treatment for childhood cancer.
Chest wall abnormalities are not well-described in the literature, and little is known on the impact on daily life of
survivors.
Methods: We investigated prevalence and risk factors of chest wall abnormalities in childhood cancer survivors in a
nationwide, population-based cohort study (Swiss Childhood Cancer Survivor Study) with a questionnaire survey.
We then interviewed a nested sample of survivors to validate types of chest wall abnormalities and understand
their impact on the daily life of survivors.
Results: Forty-eight of 2382 (95%CI 2–3%) survivors reported a chest wall abnormality. Risk factors were older age
at cancer diagnosis (16–20 years; OR 2.5, 95%CI 1.0–6.1), lymphoma (OR 3.8, 95%CI 1.2–11.4), and central nervous
system tumors (OR 9.5, 95%CI 3.0–30.1) as underlying disease, and treatment with thoracic radiotherapy (OR 2.0,
95%CI 1.0–4.2), surgery to the chest (OR 4.5, 95%CI 1.8–11.5), or chemotherapy (OR 2.9, 95%CI 1.0–8.1). The nature
of the chest wall abnormalities varied and included thoracic wall deformities (30%), deformations of the spine (5%)
or both (55%), and scars (10%). Chest wall abnormalities affected daily life in two thirds (13/20) of those who
reported these problems and necessitated medical attention for 15 (75%) survivors.
Conclusion: It is important that, during follow-up care, physicians pay attention to chest wall abnormalities, which
are rare late effects of cancer treatment, but can considerably affect the well-being of cancer survivors.
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Background
Chest wall abnormalities have been reported in a widely
variable proportion of childhood cancer survivors. Avail-
able studies were small, including 16 to 143 participants
[1–9], or focused on patients with selected cancer diag-
noses only, e.g., chest wall sarcoma [1], central nervous
system (CNS) tumours [10], neuroblastoma [2, 9], or
Wilms tumour [3, 4]. Some studies reported on specific
cancer treatments such as thoracic radiotherapy, radio-
therapy to the spine [6], abdominal radiotherapy [7, 8],
or surgical interventions for solid tumours [5]. Such
studies are not representative of the entire population of
childhood cancer survivors. In large, cross-sectional
studies, 1.4% [11] (North America, multicenter study) to
2.0% [12] (Switzerland, population-based study) of survi-
vors reported chest wall abnormalities in questionnaire
surveys [10–12]. Those investigations used one single
question on chest wall abnormalities, which did not en-
able understanding of the type of chest wall abnormal-
ities as no exact definition was attached to the question.
Survivors might not understand the term “chest wall ab-
normalities” in the way researchers intend. They might
choose to report different health issues as chest wall ab-
normalities, including thoracic wall deformities, spinal
deformities, breast asymmetries, or scars. No study in-
vestigated whether and how chest wall abnormalities
affect the daily life of survivors and if medical care is
needed.
With this study, we wanted to expand the epidemio-
logical knowledge on chest wall abnormalities in survi-
vors. First, we assessed the prevalence of chest wall
abnormalities reported by survivors in Switzerland and
investigated cancer and cancer-treatment-related risk
factors for chest wall abnormalities. Second, we inter-
viewed a nested sample of survivors to validate and clar-
ify the type of chest wall abnormalities reported by
survivors and their impact on daily life. Last, we con-
ducted a systematic review of the available literature on
chest wall abnormalities in childhood cancer survivors.
Methods
Swiss childhood Cancer survivor study
The Swiss Childhood Cancer Survivor Study (SCCSS) is
a population-based, long-term follow-up study of pa-
tients registered in the Swiss Childhood Cancer Registry
(SCCR, www.childhoodcancerregistry.ch). Participants
have been diagnosed with leukemia, lymphoma, CNS tu-
mors, malignant solid tumors, or Langerhans cell histio-
cytosis after 1976 and before the age of 21 years.
Participants, who have survived ≥5 years since initial
cancer diagnosis and were alive at the time of the study,
received a questionnaire between 2007 and 2013. Nonre-
sponders received a second copy of the questionnaire
four to 6 weeks later. If they again did not answer, we
contacted them by phone. In total 2382 survivors replied
(Supplementary figure S1). Detailed methods of the
SCCSS have been published [12–14].
Outcome: chest wall abnormalities
The SCCSS questionnaire, like the North Amercian [15]
and British [16] Childhood Cancer Survivor Studies, in-
cludes one question on chest wall abnormalities in the
section on pulmonary health: “Have you ever been told
by a doctor that you have or have had changes to your
thorax and/or ribs?” and possible answers included ever
in life (yes/no), since when (year), and currently (yes/no)
(Supplementary figure S2).
Validation of outcome by telephone interview
In a nested follow-up study, we sent a letter to all survi-
vors who had reported a chest wall abnormality in the
questionnaire to invite them to take part in a telephone
interview. All those were at least 18 years old, still alive,
had consented to participation in further studies, and
had a valid telephone number. Survivors were contacted
by telephone between July 2017 and September 2017 by
one investigator (CL) (Supplementary figure S1). The
purpose of the structured interview was to determine
the medical problems underlying the reported chest wall
abnormalities. We sought information on 1) deforma-
tions of the chest wall that included asymmetric chest
wall, pectus excavatum, pectus carinatum, completely or
partially missing ribs, deformation of the breast, muscu-
lar abnormalities, or other deformations of the chest wall
or ribs; 2) deformations of the spine including scoliosis,
hyperkyphosis, hyperlordosis, or other deformations of
the spine; 3) scars on the chest wall. We also asked
about the impact of chest wall abnormalities on daily life
which could include general complaints as well as cos-
metic problems, respiration problems, flexibility impair-
ments, pain because of the chest wall abnormalities, and
impairment in activities of daily living. Finally, we asked
whether medical attention—consultation with a phys-
ician, diagnostic investigations, operations, and physio-
therapy—had been sought. The questionnaire used for
the interview is available as supplementary material in
its original form in German and as an English
translation.
The Ethics Committee of the Canton of Bern approved
the SCCR and the SCCSS (KEK-BE: 166/2014), and the
Swiss Childhood Cancer Survivor Study is registered at
ClinicalTrials.gov (identifier: NCT03297034).
Covariates: demographic and cancer-related
characteristics
We obtained cancer characteristics from the SCCR in-
cluding age at diagnosis, year of diagnosis, cancer diag-
nosis according to the International Classification of
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Childhood Cancer, 3rd edition [17], and details on radio-
therapy, surgery, and chemotherapy. We combined total
body irradiation, mantle field radiation, and radiation to
the thorax, lungs, mediastinum, or thoracic spine to
thoracic radiotherapy (yes/no). Surgery to the chest (yes/
no) included the clavicles, scapulae and ribs, tumor exci-
sion from soft tissue on thorax, thoracic muscles, thor-
acic spine, and tumor or lymph node biopsies on the
chest wall.
Statistical analysis
We reported prevalence of chest wall abnormalities overall
and stratified by sex, age at cancer diagnosis (0–5; 6–10;
11–15; 16–20), years of diagnosis (1976–1990; 1991–
2005), cancer diagnosis (leukemia; lymphoma; CNS
tumor; other tumors), and cancer treatment (thoracic
radiotherapy (yes, no); surgery to the chest (yes, no); any
chemotherapy (yes, no)). We identified demographic and
cancer-related risk factors for chest wall abnormalities
using univariable and multivariable logistic regression. All
analyses were done in Stata (Version 14; Stata Corpor-
ation, Austin, TX).
Systematic literature review
We conducted a literature review searching for relevant
articles in the two bibliographic databases PubMed and




Survivors reporting chest wall abnormalities
N = 48
(2.0, 95%CI 1.5–2.7)
n %a n %b (95%CI)
Sex
Female 1111 46.6% 16 1.4% (0.8–2.3)
Male 1271 53.4% 32 2.5% (1.8–3.5)
Age at diagnosis (years)
0–5 1108 46.5% 20 1.8% (1.2–2.8)
6–10 521 21.9% 7 1.3% (0.6–2.8)
11–15 540 22.7% 12 2.2% (1.3–3.9)
16–20 213 8.9% 9 4.2% (2.2–7.9)
Median (IQR) age at study (years) 31.1 (24.6–38.2) 32.1 (25.8–38.1)
Year of diagnosis
1976–1990 845 35.5% 18 2.1% (1.3–3.4)
1991–2005 1537 64.5% 30 2.0% (1.4–2.8)
Diagnosis
I: Leukemia 773 32.5% 5 0.6% (0.2–1.5)
II: Lymphoma 428 17.9% 16 3.7% (2.3–6.0)
III: CNS tumor 345 14.5% 13 3.8% (2.2–6.4)
IV–XII: Other tumors 836 35.1% 14 1.7% (1.0–2.8)
Thoracic radiotherapy c
No 2075 87.1% 31 1.5% (1.1–2.1)
Yes 307 12.9% 17 5.5% (3.5–8.7)
Surgery to the chest d
No 2290 96.1% 41 1.8% (1.3–2.4)
Yes 92 3.9% 7 7.6% (3.7–15.2)
Any chemotherapy
No 414 17.4% 6 1.4% (0.7–3.2)
Yes 1968 82.6% 42 2.1% (1.6–2.9)
Abbreviations: CI Confidence interval, N Number
a Column percentages are given
b Row percentages are given
c Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine
d Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy
on the chest wall
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Embase Ovid, last updated December 31st 2019. Both
databases were searched using thesaurus terms (MeSH,
Emtree) and textwords. We applied restrictions to lan-
guage and searched studies on humans only, and ex-
cluded from the search conference abstracts, letters to
the editor, and editorials. To retrieve further relevant
publications, we checked the reference lists of studies in-
cluded and added Google scholar for a full-text search.
An information specialist from the University Library of
Bern was consulted to set up the search strategies in
order to ensure optimal data acquisition.
The search results were screened in two steps by two
independent reviewers (RK, CL) and assessed according
to relevance and eligibility criteria (PRISMA flow dia-
gram). We excluded articles on deformations of the
spine (kyphosis, kyphoscoliosis, hyperlordosis, and scoli-
osis), as this was not the main focus of this project. Add-
itional articles were searched by screening the reference
list of suitable systematic reviews found in the two data-
bases. For details on search strategies and search plat-
forms, see Supplementary Text and Supplementary
figure S3.
Results
Prevalence and risk factors of chest wall abnormalities
Among the 2382 survivors who participated in the SCCS
S, 2% (48/2, 382) reported a chest wall abnormality (95%
confidence interval [95%CI] 1.5–2.7). Male survivors
were more often affected (2.5, 95%CI 1.8–3.5) than fe-
males (1.4, 95%CI 0.8–2.3) (Table 1). Median age at
Table 2 Demographic and cancer-related risk factors for chest wall abnormalities in Swiss childhood cancer survivors
Total N = 2382 Chest wall abnormalities (n = 48)
ORcrude




Male 1.8 (1.0–3.2) 1.8 (1.0–3.3)
Age at diagnosis (years) 0.125 0.017
0–5 Ref. Ref.
6–10 0.7 (0.3–1.8) 0.5 (0.2–1.2)
11–15 1.2 (0.6–2.5) 0.7 (0.3–1.6)
16–20 2.4 (1.1–5.3) 2.5 (1.0–6.1)
Year of diagnosis 0.768 0.602
1976–1990 Ref. Ref.
1991–2005 0.9 (0.5–1.7) 0.8 (0.5–1.6)
Diagnosis < 0.001 < 0.001
I: Leukemia Ref. Ref.
II: Lymphoma 6.0 (2.2–16.4) 3.8 (1.2–11.4)
III: CNS tumor 6.0 (2.1–17.0) 9.5 (3.0–30.1)
IV–XII: Other tumors 2.6 (0.9–7.3) 2.1 (0.7–6.1)
Thoracic radiotherapy d < 0.001 0.058
No Ref. Ref.
Yes 3.9 (2.1–7.1) 2.0 (1.0–4.2)
Surgery to the chest e 0.002 0.004
No Ref. Ref.
Yes 4.5 (2.0–10.4) 4.5 (1.8–11.5)
Any chemotherapy 0.348 0.029
No Ref. Ref.
Yes 1.5 (0.6–3.5) 2.9 (1.0–8.1)
Abbreviations: CI Confidence interval, OR Odds ratio, N Number, P P-value
a Odds ratio from univariable logistic regression analysis
bP-values calculated from likelihood-ratio tests comparing survivors with and without chest wall abnormality
c Odds ratio from multivariable logistic regression analysis, model adjusted for all factors shown
d Including the following radiation fields: total body irradiation, mantle field, thorax, lungs, mediastinum, or thoracic spine
e Including surgery to clavicle, scapulae and ribs, tumor excision from soft tissue on thorax, muscles on thorax, spine of thorax, and tumor or lymph node biopsy
on the chest wall
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study was 31 years (interquartile range [IQR] 25–38) and
survivors who were older at cancer diagnosis (16–20
years, 4.2, 95%CI 2.2–7.9) had a higher prevalence of
chest wall abnormalities compared to those who were
younger. Prevalence did not change over time, being 2
and 2.1% in the periods of 1976–1990 and 1991–2005.
When comparing underlying diagnoses, chest wall ab-
normalities were most frequently reported by survivors
of lymphoma (3.7, 95%CI 2.3–6.0) and CNS tumors (3.8,
95%CI 2.2–6.4), but rarely by participants treated for
leukemia (0.6, 95%CI 0.2–1.5). Nearly 8% of survivors
treated with surgery to the chest and 6% treated with
thoracic radiotherapy reported a chest wall abnormality.
In a multivariable regression, the following factors
remained independently associated with chest wall ab-
normalities: male sex (odds ratio [OR] 1.8, 95%CI 1.0–
3.3), older age at cancer diagnosis (OR 2.5, 95%CI 1.0–
6.1), lymphoma (OR 3.8, 95%CI 1.2–11.4), CNS tumor
(OR 9.5, 95%CI 3.0–30.1), thoracic radiotherapy (OR 2.0,
95%CI 1.0–4.2), surgery to the chest (OR 4.5, 95%CI
1.8–11.5), and chemotherapy (OR 2.9, 95%CI 1.0–8.1)
(Table 2).
Telephone interviews
Among the 48 survivors who reported chest wall abnor-
malities, 25 survivors were available for interview and 20
participated (80%) (Supplementary figure S1). Of the 20
interviewed, 18 were confirmed to have a chest wall ab-
normality (Table 3). When asked in more detail, 85%
(17/20) described thoracic wall deformities, 60% (12/20)
a deformation of the spine, and 70% (14/20) scars on the
chest wall. Most survivors (80%; 16/20) reported mul-
tiple problems (Fig. 1 and Table 3). Thoracic wall de-
formities included pectus excavatum (n = 4), pectus
carinatum (n = 2) and unspecified thoracic asymmetries
(n = 6), missing or deformed ribs (n = 7), and deform-
ation of the breasts (n = 1). Deformation of the spine in-
cluded scoliosis (n = 7), hyper kyphosis (n = 4), and
hyper lordosis (n = 3).
We also asked survivors whether the chest wall abnor-
malities affected their daily life and if they had sought
medical attention. Among the 20 survivors interviewed,
13 survivors said that the chest wall abnormality affected
respiration, flexibility, and activities of daily life, caused
cosmetic problems, or pain (Table 3). Fifteen survivors
had sought medical attention. Fourteen consulted a doc-
tor (10 visited one specialist only and four visited mul-
tiple specialists). Specialists included general
practitioners, pediatric oncologists, orthopedists, chiro-
practors, surgeons, sport physicians, or rheumatologists.
Nine survivors underwent diagnostic testing, six had a
chest x-ray only and three a chest x-ray and lung func-
tion tests. One survivor needed surgery and six received
physiotherapy (Table 3).
Literature review
Of the 2167 potentially relevant articles identified, we
excluded 1935 articles after screening of title and ab-
stracts, leaving 244 articles for full-text screening. Of
those, we excluded a further 232 articles that did not
meet the inclusion criteria (Supplementary figure S3).
We summarize the remaining in Table 4. Among these,
only two investigated an unselected cohort of survivors
with regard to cancer diagnosis and treatment [11, 12].
Both used postal questionnaires (the Swiss and North
American Childhood Cancer Survivor Studies) and
found a prevalence of chest wall abnormalities of
2.0% [12] and 1.3% [11]. Six studies focused on survi-
vors of selected cancer diagnoses [1–4, 9, 10]. Lucas
et al. studied 23 survivors of chest wall sarcoma in
the USA and found that one survivor (4%) had a
ctCAE (Common Terminology Criteria for Adverse
Events) Grade IV bone abnormality of the chest [1].
Utriainen et al. found that one of 21 (5%) Finnish
survivors of high-risk neuroblastoma treated with
Table 3 Impact of chest wall abnormalities on the daily life of
survivors, and medical attention required because of chest wall
abnormality
N = 20 Proportion (%)
Impact of chest wall abnormalities on daily life
Any impact 13 65%
Respiration 8 40%
Flexibility 7 35%
Activities of daily living 6 30%
Cosmetic 6 30%
Pain 6 30%
Required medical attention because of chest wall abnormality
Any medical attention 15 75%
Consultation a 14 70%
1 specialist visited 10 50%
> 1 specialist visited 4 20%
Diagnostic investigation b 9 45%
Chest X-ray 6 30%
Chest X-ray + lung function test 3 15%
Operations 1 5%
Physiotherapy 6 30
Abbreviations: N Number; Respiration, any respiratory impairment; Flexibility,
impairment of flexibility; Activities of daily living, inability or problems when
performing activities of daily living such as housekeeping; Cosmetic, disturbed
by the cosmetic appearance of the chest wall abnormality; Pain, any pain
because of the chest wall abnormality; Consultation, ever consulted a medical
doctor because of the chest wall abnormality; Diagnostic investigation, had
further diagnostic testing because of the chest wall abnormality (e.g., chest x-
ray, lung function tests); Operations, had an operation because of the chest
wall abnormality; Physiotherapy, visited physical therapy because of the chest
wall abnormalities
a Survivors reported consultations with: general practitioner n = 5, pediatric
oncologist n = 4, oncologist n = 1, orthopedist n = 3, chiropractor n = 1,
surgeon n = 1, sports physician n = 1, rheumatologist n = 1
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hematopoietic stem cell transplantation had a sternal
asymmetry [9]. Huang et al. found that, in the North
American Childhood Cancer Survivor Study of 1653
survivors, 15 (0.4%) had a chest wall abnormality [10].
Perwein et al. studied 16 stage 4 neuroblastoma survi-
vors and found that, of four (25%) with musculoskel-
etal late effects, one (6%) had an asymmetric pectus
carinatum [2]. Tröbs et al. reported chest wall de-
formity in three (6%) of 49 German Wilms tumor
survivors [3]. Heaston et al. studied 25 US Wilms
tumor survivors and found radiographic evidence of
abnormal skeletal development in 24 (96%) and hypo-
plasia of the pelvis and/or thorax in 13 (52%) [4].
Four studies focused on specific cancer treatments
only [5–8]. Venkatramani et al. found that, of 109 US
survivors treated with radiotherapy to the lungs with-
out total body irradiation or whole lung irradiation,
eleven (10%) had a chest wall abnormality—of those
11, one (1%) had hypoplasia of the chest wall [8].
Pintér et al. studied survivors who were operated on
for solid malign tumors in Hungary [5]. In those with
surgical treatment only (n = 15), four (27%) had a
thoracic deformity and twelve (80%) had scar forma-
tion resulting in psychological problems. In those
with multimodal therapy (n = 64), two (3%) had skin
lesions following radiotherapy, seven (11%) had a
muscular deformity, five (8%) had bone morbidity
(underdevelopment), three (5%) had a decreased phys-
ical ability to work, four (6%) had a thorax deformity,
seven (11%) had breast underdevelopment, and twelve
(19%) had scar formation resulting in psychological
problems. Butler et al. found that, of 143 US survi-
vors 1 year after irradiation to the spine and/or ex-
tremities, 51 (36%) had a chest and rib deformity and
23 (16.%) had significant pain at the radiation sites
[6]. Taylor et al. found that, out of 138 survivors of
Wilms tumor after abdominal radiotherapy, 27 (19%)
had musculoskeletal late effects, thirteen (9%) had
asymmetry, six (4%) hypolplasia, one (0.7%) breast
asymmetry, and one (0.7%) rib hypoplasia [7].
Studies that focused on selected outcomes or treat-
ments reported a higher prevalence of chest wall abnor-
malities than studies based on unselected survivor
cohorts (Table 4).
Discussion
This is the first study to describe self-reported chest wall
abnormalities in an unselected, representative sample of
childhood cancer survivors in detail, and to validate an-
swers in a structured interview. Two percent of all survi-
vors reported a chest wall abnormality. We found a
broad range of problems that were summarized as chest
wall abnormalities. More than half of interviewed survi-
vors were affected in their daily lives and three quarters
required medical attention.
A strength of this study is that we clarified types of
chest wall abnormalities and their impact on daily life by
directly interviewing survivors. Survivors could explain
Fig. 1 Proportional Venn diagram showing reported types and overlap of chest wall abnormalities in childhood cancer survivors in the
telephone interview
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their problems and we could inquire about the impact of
their chest wall abnormalities. We were able to reach
80% of eligible survivors who had reported a chest wall
abnormality in the SCCSS questionnaire. Participants
did not differ from nonparticipants (results not shown)
and a previous study concluded that response bias in the
SCCSS did not markedly influence prevalence estimates
[18]. A limitation of this study is that we were not able
to validate chest wall abnormalities in survivors with
medical exams or x-rays. A medical examination or
chest x-ray would have helped to further quantify type
and severity of the reported problems.
The prevalence of chest wall abnormalities in this
study and in a previously published study from
Switzerland with an overlapping population [12] was
only slightly higher than in the North American Child-
hood Cancer Survivors Study (2.0% versus 1.3%) [11].
These two studies present data with similar methods
(questionnaire survey) in an unselected cohort in respect
to diagnoses and cancer treatment in either a national or
multicenter set up. A further report of the North Ameri-
can Childhood Cancer survivors study on CNS tumor
survivors found chest wall abnormalities in 0.4% of sur-
vivors—this is lower than in the group of CNS tumor
survivors in our study (4%) [10]. Treatment-related fac-
tors like the frequency and cumulative dose of thoracic
radiotherapy (such as spinal radiation in CNS tumor pa-
tients) might differ between countries and help to ex-
plain such differences in prevalence of chest wall
abnormalities. Other studies and case series focusing on
diagnostic subgroups mostly reported higher prevalence
of chest wall abnormalities (4–52%) [1–4, 9]. They were
all small, with 49 or less participants, and included high-
risk tumor survivors who were exposed to intensive
multimodal cancer treatment (stage 4 or high-risk
neuroblastoma [2, 9]), survivors with tumors on the
chest wall (chest wall sarcoma [1]), or diagnosed a long
time ago, where radiotherapy and surgical approaches
were far more invasive than today which in general sets
survivors at higher risk of developing late effects [3, 4].
Four other studies focused on survivors of specific can-
cer treatments such as radiotherapy to the lungs [8],
spine/extremities [6], or abdomen [7], or surgery of solid
malign tumors [5] reported chest wall abnormalities in
1–36% of participants. In our study, those treated with
thoracic radiotherapy or surgery to the chest had higher
prevalence of chest wall abnormality than those without,
reflecting the findings of the other studies.
Risk factors for chest wall abnormalities in survivors
vary between studies. Our study is the first to report
older age at diagnosis (16–20 years) as a risk factor for
chest wall abnormalities. Peak bone growth velocity and
increase of peak bone mass happen during puberty [19],
therefore cancer treatment during this vulnerable time
may affect the development of the spine and thoracic
wall more severely than treatment earlier in childhood.
CNS tumor survivors were most likely to report chest
wall abnormalities. CNS tumors are often treated with
radiotherapy to the spine, which is another risk factor
identified in our study (OR 2.0; 95%CI 1.0–4.2), in the
North American Childhood Cancer Survivor Study (rate
ratio 5.0) [11], and in other studies [5–8]. Also, CNS
tumor survivors often suffer from comorbidities that in-
clude small stature, functional deficits, endocrine dis-
eases, fatigue, and psychological problems [20], which
might lead to a higher subjective burden of chest wall
abnormalities compared to other survivor groups.
We could validate chest wall abnormalities in 18 of 20
survivors who indicated a chest wall abnormality in the
SCCSS questionnaire. Two survivors had scars only
(which they reported as chest wall abnormalities) and 12
had both scars and chest wall abnormalities. This suggests
that not all survivors understood the term “chest wall ab-
normality” as was intended by the questionnaire. We sug-
gest that future questionnaires describe chest wall
abnormalities in more detail or use open questions to fur-
ther assess the type of chest wall abnormality. For physi-
cians involved in follow-up care of childhood cancer
survivors, awareness of chest wall abnormalities should be
raised and clinical examinations performed to quantify the
extent of individual problems and limitations.
Many participants were affected in daily life by chest
wall abnormalities, which reflects the severity of this rare
late effect after childhood cancer treatment. The most
common complaints were impaired flexibility and phys-
ical fitness. An interdisciplinary treatment approach
could help improve these issues. Early physiotherapy
could be used in survivors at risk of developing chest
wall abnormalities to improve late functional outcomes
and might also reduce pain.
Conclusion
In conclusion, this study suggests that, even though
chest wall abnormalities are rare in the entire childhood
cancer survivor population, they have a considerable im-
pact on survivors’ lives. Physicians should pay close at-
tention to these problems during follow-up care.
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